Clinical Trials Logo

Filter by:
NCT ID: NCT02404090 Not yet recruiting - Obesity Clinical Trials

Impact of the Excess Weight Loss on Mineralization Patterns of the Knee After Bariatric Operations

CT-OAM
Start date: August 2015
Phase: N/A
Study type: Observational

Evaluation of the subchondral mineralization plate after excess weight loss in patientes undergoing bariatric operation by means of CT-osteoabsorptiometry.

NCT ID: NCT02406417 Not yet recruiting - Clinical trials for Pituitary Dysfunction

Reflective Testing for Early Diagnosis of Pituitary Dysfunction

Start date: August 2015
Phase: N/A
Study type: Interventional

Early detection and management of pituitary dysfunction reduces the morbidity that ensues as a consequence of missed or delayed diagnosis of this condition, and which may result in life-threatening events and increased mortality. The investigators study will explore the use of reflex strategies within the laboratory in capturing suspicious pituitary function test results from Primary Care patients and following these up with appropriate reflective testing. Subsequently patients identified from these results to have a possible underlying piuitary dysfunction will have an alert sent to their family physician prompting referral to the Endocrine team for further investigation and management.

NCT ID: NCT02415699 Not yet recruiting - Colorectal Cancer Clinical Trials

DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer

Start date: August 2015
Phase: Phase 2/Phase 3
Study type: Interventional

Stage III colorectal cancer constitutes more than half of the colorectal patients, and the prognosis does not improve much recently although varies of adjuvant drugs have been tried. DC-CIK immunotherapy has been proved to improve survival in cancer patients, but its role in stage III colorectal cancer patients stains unclear. The investigators study will focus on the efficacy and safety of DC-CIK immunotherapy plus chemotherapy in the adjuvant treatment of stage III colorectal cancer, compared with chemotherapy alone.

NCT ID: NCT02441257 Not yet recruiting - Clinical trials for Gastroesophageal Reflux

Gastroesophageal Reflux During LMA in Control Ventilation (LMA, Laryngeal Mask Airway)

LMA
Start date: August 2015
Phase: N/A
Study type: Interventional

Laryngeal mask airway is seldom used for control ventilation in America, while it is popular in China. The question is whether the incidence of gastroesophageal reflux in control ventilation is really higher than in spontaneous ventilation. So the investigators combine the third generation laryngeal mask and catheter-based Digitrapper ph-Z monitor system to evaluate the exact incidence of gastroesophageal reflux in these two groups.

NCT ID: NCT02452151 Not yet recruiting - Crohn's Disease Clinical Trials

"Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial"

SIMILAR
Start date: August 2015
Phase: Phase 4
Study type: Interventional

The objective of this study is to compare the efficacy of Infliximab-Biosimilar to Infliximab-Innovator and to demonstrate its noninferiority, in patients with ulcerative colitis or Crohn's disease in remission under treatment with infliximab up to 3 months.

NCT ID: NCT02475863 Not yet recruiting - Clinical trials for Congenital Heart Defects

Model-based Versus Traditional Warfarin Dosing in Children

WATCH
Start date: August 2015
Phase: N/A
Study type: Interventional

This study compares the clinical effectiveness of a new algorithm (model-based warfarin dosing) with standard practice (doctor's own judgement and intuition) designed to determine the most appropriate anticoagulant dose of warfarin in children after congenital heart surgery.

NCT ID: NCT02476331 Not yet recruiting - Bipolar Disorder Clinical Trials

A Trial of Cognitive Training in Euthymic Bipolar Disorder

Start date: August 2015
Phase: N/A
Study type: Interventional

Bipolar disorder (BD) is characterized by extreme changes in mood and emotion dysregulation. Mood changes are episodic in nature, with distinct periods of mania, depression, and asymptomatic periods of euthymia. In addition to impairments in mood, cognitive impairments are a common feature of the disorder. These cognitive impairments persist during periods of euthymia and are associated with negative clinical and psychosocial outcomes. Specifically, individuals with BD show impairments in executive functions. Recent studies show that emotion regulation can be down-regulated by taxing executive functions, and it can be improved with working memory training, a specific component of executive functions. These initial studies show that emotion regulation is under executive control in healthy individuals; however, the nature of this relationship is not well understood in populations that are affected by impairments in both executive control and emotion regulation. Previous work on cognitive training has not targeted specific cognitive domains with an emphasis on understanding the underlying mechanisms that promote change. Moreover, well-controlled randomized control trial (RCT) studies are needed in order to provide high quality evidence to inform the efficacy of cognitive training interventions for psychiatric populations. The aim of the proposed study is to use a commercially available cognitive training program to study the effects of working memory training on cognitive, clinical, and psychosocial outcomes in patients with BD. We hypothesize that training working memory will lead to improvements in cognitive and emotional functioning, leading to downstream changes that will positively impact untrained outcomes, such as mood and community functioning.

NCT ID: NCT02487550 Not yet recruiting - Renal Neoplasma Clinical Trials

DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating

Start date: August 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to show if vaccination with autologous dendritic cells pulsed with tumor lysate in combination with Cytokine-Induced Killer Cell (CIK) can induce a measurable immune response in patients with renal cell carcinoma, and to evaluate the clinical effect of the regimen.

NCT ID: NCT02488603 Not yet recruiting - Breast Cancer Clinical Trials

Decision Aids for Tamoxifen Treatment in Breast Cancer Patients

Start date: August 2015
Phase: N/A
Study type: Interventional

This is an educational intervention study for breast cancer patients who undergo tamoxifen treatment. The purpose of the study is to assess the impact of decision aids (DA) on the patients' decision-making process, compliance on drug, and knowledge regarding tamoxifen treatment. Patients will randomly assign to DA group or conventional group. Both groups will have baseline questionnaire surveys before starting tamoxifen treatment, and 4 weeks later follow-up questionnaire surveys.

NCT ID: NCT02489929 Not yet recruiting - Clinical trials for Myelodysplastic Syndromes

Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine

Start date: August 2015
Phase: N/A
Study type: Interventional

Myelodysplastic syndrome (MDS) is a group of medical conditions derived from progressive bone marrow failure that result in ineffective production of blood cells. Depending on the severity, MDS reduces the quality of life to the point of being life-threatening. There is a probability of death at all stages of the disease, due to complications and co-morbidities, with progression to acute myeloid leukemia (AML) being the worst evolution. Azacytidine is a nucleosidic analog with original epigenetic mechanism of action that is widely used for treating a variety of myelodysplasic syndromes. Although generally well tolerated, severe and sometimes life-threatening toxicities were unexpectedly observed in some patients. Genetic polymorphism affecting cytidine deaminase (CDA), the liver enzyme responsible for azacytidine detoxification step, could be responsible for poor clinical outcome due to on the one hand to severe toxicities in deficient patients, and on the other hand on treatment failure in ultrametabolizer patients.This clinical study aims at correlating the values in CDA levels with the risk of drug-related toxicities and to the clinical response to azacytidine treatment.